This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Welireg — Description, Dosage, Side Effects | PillsCard
OTC
Welireg
INN: belzutifan
Data updated: 2026-04-25
Available in:
🇨🇿🇩🇪🇬🇧🇫🇷🇵🇹🇹🇷
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Merck Sharp & Dohme B.V.
ATC Code
L01XX74
Source
EMA · EMEA/H/C/005636
(
ARTG
)
von Hippel-Lindau (VHL) disease associated tumours,WELIREG (belzutifan) is indicated for the treatment of adult patients with von Hippel-Lindau
(VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous
system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), not
requiring immediate surgery.,Advanced Renal Cell Carcinoma (RCC),WELIREG (belzutifan) is indicated for the treatment of adult patients with advanced renal cell
carcinoma (RCC) following a programmed cell death 1/ligand 1 (PD-1/L1) and a vascular
endothelial growth factor (VEGF)-targeted therapy.